In recent years, monoclonal antibodies either as a single agent or in combination with chemotherapy, have made a dramatic impact in the outcome of patients with most B-cell NHL types. Maintenance ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... Patients with lymphoma whose disease has returned after several lines of therapy have a very poor prognosis, with ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Kymriah was cleared by the FDA for the follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... Patients with lymphoma whose disease has returned after several lines of therapy have a very poor prognosis, with ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).